Head of European Market Access – Oncology (Solid Tumors)

**About Summit:** Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit's core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit's team is inspired to touch and help change lives through Summit's clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: **Non-small Cell Lung Cancer (NSCLC)** * HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. * HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. * HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. **Colorectal Cancer (CRC)** * HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. *Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.* **This role can be based in:** Zug, Switzerland / Dublin, Ireland / Oxford, UK **Overview of Role:** We are seeking a highly accomplished and strategic European Market Access Leader to drive pricing, reimbursement, health technology assessment, and patient access strategies for our oncology portfolio across Europe. The successful candidate will bring deep expertise in European oncology market access, with particular experience in solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and bladder/urothelial cancer. This individual will play a critical leadership role in shaping European commercialization strategies, ensuring optimal market access, reimbursement, and sustainable pricing for innovative oncology therapies. The ideal candidate will possess strong knowledge of the evolving European payer landscape, national and regional reimbursement systems, oncology treatment pathways, competitive dynamics, and the clinical and economic evidence required to secure